The approval covers Somapacitan Injection 5 mg/1.5 ml, 10 mg/1.5 ml and 15 mg/1.5 ml solution for injection in pre-filled pen (PFP), indicated for the treatment of growth hormone deficiency.
During the meeting, the firm presented its proposal to conduct following India-specific PMS studies for the approved drug product Somapacitan Injection 5 mg/1.5 ml, 10 mg/1.5 ml and 15 mg/1.5 ml solution for injection in PFP -
i. A multicenter, prospective, single-arm, observational, non-interventional, postmarketing surveillance study to investigate safety of somapacitan in adults with growth hormone deficiency (AGHD) under routine clinical practice in India vide Protocol No. NN8640-8387, Version 1.0 dated 29 Jul 2025.
ii. A Non-Interventional, Observational Study to Investigate Long-Term Safety and Clinical Parameters of Somapacitan Treatment in Paediatric Patients with Growth Hormone Deficiency During Routine Clinical Practice in India vide Protocol No. NN8640-8388, Version 1.0 dated 29 Jul 2025.
Somapacitan is a human growth hormone analog indicated for adults with growth hormone deficiency. Somapacitan binds to the growth hormone receptor and induces intracellular signalling to up-regulate insulin-like growth factor I (IGF-1). IGF-1 causes growth in bones and muscle tissue. Growth hormones more directly cause the fusion of myoblasts and myotubes to cause muscle fiber growth, activate neural stem cells, and induce chondrocyte proliferation.
Somapacitan is indicated as a replacement for growth hormone in adult patients with growth hormone deficiency.
At the recent SEC meeting, the expert panel reviewed the proposal presented by Novo Nordisk India to conduct India-specific PMS studies for the approved drug product Somapacitan Injection 5 mg/1.5 ml, 10 mg/1.5 ml and 15 mg/1.5 ml solution for injection in PFP.
After detailed deliberation, the committee recommended the approval to conduct the proposed PMS studies as per protocols presented by the firm.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.